Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Down 57.0% in September

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 37,000 shares, a drop of 57.0% from the August 31st total of 86,000 shares. Based on an average daily volume of 176,300 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Coeptis Therapeutics

A hedge fund recently raised its stake in Coeptis Therapeutics stock. Armistice Capital LLC grew its position in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by 59.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,520,000 shares of the company’s stock after buying an additional 1,308,000 shares during the quarter. Armistice Capital LLC owned 10.32% of Coeptis Therapeutics worth $2,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 13.88% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH lowered Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 18th.

Coeptis Therapeutics Trading Down 3.1 %

NASDAQ:COEP opened at $0.16 on Friday. The stock has a market cap of $6.02 million, a price-to-earnings ratio of -0.31 and a beta of -0.91. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average price is $0.21 and its 200-day moving average price is $0.28. Coeptis Therapeutics has a 52 week low of $0.16 and a 52 week high of $1.38.

Coeptis Therapeutics (NASDAQ:COEP) last issued its earnings results on Friday, August 16th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. On average, equities research analysts forecast that Coeptis Therapeutics will post -0.26 earnings per share for the current fiscal year.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.